The latest medical insurance regulations for Dasatinib

It is understood that the original drug of Dasatinib (Dasatinib) is already on the market in China. According to the relevant regulations of the National Medical Insurance Administration, the original drug has been included in the reimbursement scope of Class B medical insurance. Reimbursement is limited to eligible patients, that is, for For patients with chronic myeloid leukemia (CML) who are resistant or intolerant to imatinib, eligible patients need to purchase the drug at the local medical insurance bureau for reimbursement based on the prescription information. Due to differences in reimbursement ratios, the reimbursement prices may be different, and patients who are not eligible can only purchase the drug at their own expense.

Resistance to imatinib has led to the development of newTKIs. The second-generation TKI dasatinib was approved by the U.S. Food and Drug Administration (FDA) in 2010 with an initial dose of 100 mg once daily for patients with chronic phase CML and 70 mg twice daily for the treatment of patients with chronic phase, blast crisis, or accelerated phase CML who are resistant or intolerant to previous therapy. including imatinib. Various clinical trials have provided evidence of longer-lasting complete hematological and cytogenetic responses and greater efficacy compared with imatinib.

The current domestically marketed dasatinib original drug, common specificationsThe price of each box of 50mg*60 tablets may be around 10,000 yuan. The overseas original drug is more expensive, and the high price may increase the financial pressure on some families. Generic drugs of dasatinib are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of 50mg*60 tablets produced by an Indian pharmaceutical factory may be RMB 500 per box (the price may fluctuate due to the exchange rate). For more drug information and specific prices, please consult Yaode Medical Consultant.